首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice
【24h】

Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice

机译:肝肾综合征,MELD评分和肝移植:一个不断发展的问题,对临床实践具有重要意义

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Hepatorenal syndrome (HRS) is a severe complication of cirrhosis that is associated with poor survival. A rapid diagnosis of HRS and a prompt initiation of the treatment with terlipressin and albumin are mandatory because this leads to an improvement of prognosis. This review covers the predictive value of HRS on 3-month mortality beyond the MELD score and its consequential impact on the prioritization policy to liver transplantation (LT). Moreover, it analyzes the impact of the response to pharmacological treatment on the MELD score, its possible delaying effect on the timing of LT, and suggests a way of overcoming the paradoxical effect of terlipressin and albumin on the priority to LT in responders. Finally, the review discusses the appropriate use of combined liver-kidney transplantation (CLKT) in patients with HRS who do not respond to treatment with terlipressin and albumin.
机译:肝肾综合征(HRS)是严重的肝硬化并发症,与生存不良有关。必须快速诊断HRS并迅速开始使用特利加压素和白蛋白治疗,因为这会改善预后。这篇综述涵盖了HRS对超出MELD评分的3个月死亡率的预测价值,以及其对肝移植优先策略的影响。此外,它分析了药物治疗反应对MELD评分的影响,其对LT时机的可能延迟作用,并提出了一种克服特利加压素和白蛋白对响应者中LT优先性的悖论作用的方法。最后,本综述讨论了对特利加压素和白蛋白治疗无反应的HRS患者应适当使用肝肾联合移植(CLKT)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号